 |
 Video: What is a Stock Split?
|
|
|
| Taiwan Liposome is a clinical-stage pharmaceutical company dedicated to the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Co.'s product candidates include: TLC599, which is an intraarticular, or in-joint, injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP) for the management of osteoarthritis pain; TLC590, which is a non-opioid, BioSeizer formulation of the API ropivacaine for post-surgical pain management; and TLC399, which is a multilamellar and multivesicular BioSeizer formulation of DSP for ophthalmology indications. According to our TLC stock split history records, TLC has had 0 splits. | |
|
TLC (TLC) has 0 splits in our TLC stock split history database.
Looking at the TLC stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TLC shares, starting with a $10,000 purchase of TLC, presented on a split-history-adjusted basis factoring in the complete TLC stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
11/23/2018 |
|
| End date: |
09/28/2021 |
|
| Start price/share: |
$6.10 |
|
| End price/share: |
$7.00 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
14.75% |
|
| Average Annual Total Return: |
4.95% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$11,474.35 |
|
| Years: |
2.85 |
|
|
|
|
|
